Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Stabilisation Notice

13 Mar 2014 07:01

RNS Number : 2131C
Circassia Pharmaceuticals PLC
13 March 2014
 



NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT OR ANY COPY OF IT

 

CIRCASSIA PHARMACEUTICALS PLC

 

Stabilisation Notice

 

 

13 March 2014

 

J.P. Morgan Securities plc (contact: Manuel Esteve; telephone: +44 (0)20 7742 4000) hereby gives notice that it may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

 

The securities:

 

Issuer:

 

Circassia Pharmaceuticals plc

Shares:

 

Ordinary Shares of 0.08 pence each (ISIN: GB00BJVD3B28)

 

Offering size:

 

67,419,356 Shares

Offer price:

 

310 pence per Share

Stabilisation:

 

Stabilising Manager:

 

J.P. Morgan Securities plc

Stabilisation period expected to start on:

 

13 March 2014

Stabilisation period expected to end no later than:

 

11 April 2014

Maximum size of over-allotment facility:

 

10,112,903 Shares

Greenshoe Option:

 

Terms:

The Issuer has granted to J.P. Morgan Securities plc, in its capacity as stabilising manager, the option to acquire up to an additional 10,112,903 Shares

 

 

Duration:

This option may be exercised by the Stabilising Manager in whole or in part on one or more occasions at any time from 13 March 2014 to 11 April 2014

 

In connection with the offer of the above securities, the Stabilising Manager may over-allot the securities or effect transactions with a view to supporting, stabilising or maintaining the market price of the securities at a level which might not otherwise prevail in the open market. However, there is no assurance that the Stabilising Manager will take any stabilisation action and any stabilisation action, if begun, may be ended at any time without prior notice.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement is not for publication, distribution or release, in whole or in part, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"), Australia, Canada, Japan or any other jurisdiction where distribution would be unlawful. This announcement does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States, Australia, Canada, Japan or any other jurisdiction where such an offer would be unlawful.

 

The securities of the Issuer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The securities referred to herein have not been registered under the applicable securities laws of Australia, Canada or Japan and, subject to certain exceptions, may not be offered or sold within Australia, Canada or Japan or to any national, resident or citizen of Australia, Canada or Japan. The distribution of this announcement in other jurisdictions may be restricted by law and persons into whose possession this announcement comes should inform themselves about, and observe such restrictions.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are "qualified investors" within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be made) and must not be acted on or relied on by other persons in that Member State.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAJJMFTMBIBMAI
Date   Source Headline
18th Jan 20192:22 pmRNSBlock listing Interim Review
4th Jan 20191:48 pmRNSResult of General Meeting
4th Jan 20197:00 amRNSGeneral Meeting Business Update
31st Dec 20187:00 amRNSTotal Voting Rights
27th Dec 20187:00 amRNSHolding(s) in Company
17th Dec 20187:00 amRNSListing Rule 9.6.14(R) Disclosure
11th Dec 201812:10 pmRNSOption exercised for Tudorza from AstraZeneca
10th Dec 20185:59 pmRNSPosting of Shareholder Circular
10th Dec 201812:59 pmRNSProposed admission to trading on AIM
30th Nov 20187:00 amRNSTotal Voting Rights
31st Oct 20182:13 pmRNSTotal Voting Rights
25th Oct 20183:00 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSTotal Voting Rights
27th Sep 20187:00 amRNSInterim Results for Six Months Ended 30 June 2018
7th Sep 201811:36 amRNSNotice of Interim Results and Broker Appointment
3rd Sep 201812:15 pmRNSTotal Voting Rights
16th Aug 20184:25 pmRNSDirector Declaration
13th Aug 20187:00 amRNSRegulatory Application
31st Jul 20187:00 amRNSTotal Voting Rights
18th Jul 20184:14 pmRNSHolding(s) in Company
18th Jul 20184:12 pmRNSHolding(s) in Company
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 20181:52 pmRNSIssue of Equity and Total Voting Rights
16th Jul 20183:28 pmRNSResult of AGM
2nd Jul 20187:00 amRNSBlock listing Interim Review
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 201812:23 pmRNSPublication of Circular
11th Jun 20184:20 pmRNSHolding(s) in Company
4th Jun 20184:18 pmRNSDirector/PDMR Shareholding
4th Jun 20184:15 pmRNSDirector/PDMR Shareholding
4th Jun 20184:14 pmRNSDirector/PDMR Shareholding
1st Jun 20187:00 amRNSUS Filing of Duaklir NDA & Tudorza Supplement NDA
31st May 20187:00 amRNSTotal Voting Rights
30th May 201812:05 pmRNSResult of AGM
22nd May 20187:00 amRNSPositive Data Presented at 2018 ATS Conference
18th May 201810:57 amRNSBlock listing Interim Review
14th May 20183:37 pmRNSHolding(s) in Company
30th Apr 20185:08 pmRNSTotal Voting Rights Update
27th Apr 20184:45 pmRNSAnnual Financial Report and Notice of AGM
26th Apr 20185:46 pmRNSHolding(s) in Company
26th Apr 20185:46 pmRNSHolding(s) in Company
24th Apr 20187:00 amRNSFinal Results
24th Apr 20187:00 amRNSIssue of Equity - AstraZeneca
12th Apr 20187:00 amRNSNotice of Results
29th Mar 20187:00 amRNSTotal Voting Rights
16th Mar 20184:40 pmRNSSecond Price Monitoring Extn
16th Mar 20184:35 pmRNSPrice Monitoring Extension
28th Feb 20182:01 pmRNSTotal Voting Rights
13th Feb 20187:00 amRNSDirectorate Change
8th Feb 20187:00 amRNSReceives Innovative Tech Contract from Vizient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.